Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 114, Issue 7, Pages 1051-1070Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000000305
Keywords
-
Categories
Funding
- AbbVie Canada
- Janssen Canada
- Pfizer Canada
- Shire Canada
- Takeda Canada
- Bingham Chair in Gastroenterology
- Genome Canada
- Canadian Institutes of Health Research
- National Science and Engineering Council
- MS Society of Canada
- CANARIE Inc.
- Ontario Ministry of Agriculture, Food and Rural Affairs
Ask authors/readers for more resources
There is a growing appreciation for the role of the gut microbiome in human health and disease. Aided by advances in sequencing technologies and analytical methods, recent research has shown the healthy gut microbiome to possess considerable diversity and functional capacity. Dysbiosis of the gut microbiota is believed to be involved in the pathogenesis of not only diseases that primarily affect the gastrointestinal tract but also other less obvious diseases, including neurologic, rheumatologic, metabolic, hepatic, and other illnesses. Chronic immune-mediated inflammatory diseases (IMIDs) represent a group of diseases that share many underlying etiological factors including genetics, aberrant immunological responses, and environmental factors. Gut dysbiosis has been reported to be common to IMIDs as a whole, and much effort is currently being directed toward elucidating microbiome-mediated disease mechanisms and their implications for causality. In this review, we discuss gut microbiome studies in several IMIDs and show how these studies can inform our understanding of the role of the gut microbiome in inflammatory bowel disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available